BioSpecifics Technologies Corp. (OTC BB: BSTC)

BioSpecifics Technologies Corp. (OTC BB: BSTC), a biopharmaceutical company, has developed and licensed injectable collagenase for three clinical indications. Their development and licensing agreement with Auxilium Pharmaceuticals (Nasdaq GM: AUXL) is for clinical indications in Dupuytren’s disease, Peyronie’s disease and frozen shoulder (adhesive capsulitis). Currently, all of their efforts are focused on the future development and commercialization of injectable collagenase products. For further information, visit the Company’s web site at www.biospecifics.com.